PolyPid (PYPD) CFO details extensive employee stock option awards
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
PolyPid Ltd. Chief Financial Officer Jonathan Missulawin filed an initial ownership report listing multiple employee stock options over Ordinary Shares. These options cover various blocks of shares, including 64,500 underlying shares at an exercise price of 4.6400 and 42,000 underlying shares at 2.6700, with expirations ranging from 2027 to 2035. The filing records existing derivative holdings and does not show any stock purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
11 transactions reported
Mixed
11 txns
Insider
Missulawin Jonathan
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Employee Stock option (right to buy) — 20 shares (Direct)
Footnotes (1)
- The options were granted on March 8, 2017 and fully vested as of March 8, 2020. The options were granted on November 2, 2017 and fully vested as of November 2, 2020. The options were granted on February 6, 2020 and fully vested as of February 6, 2023. The options were granted on June 11, 2020 and vest on a quarterly basis beginning September 11, 2021 until June 11, 2024. The options were granted on May 9, 2022 and vest on a quarterly basis beginning August 9, 2023 until May 9, 2026. The options were granted on August 9, 2021 and vest on a quarterly basis beginning November 9, 2022 until August 9, 2025. The options were granted on August 7, 2023 and vest on a quarterly basis beginning November 7, 2024 until August 7, 2027. The options were granted on May 6, 2024 and vest on a quarterly basis until May 6, 2028. The options were granted on May 6, 2024 and vest on a quarterly basis until May 6, 2026. The options were granted on May 12, 2025 and vest on a quarterly basis until May 12, 2029. The options were granted on May 12, 2025 and vest on a quarterly basis until May 12, 2027.
FAQ
What does PolyPid (PYPD) CFO Jonathan Missulawin report in this Form 3?
He reports his existing employee stock option holdings over PolyPid Ordinary Shares. The filing lists multiple option grants with specific exercise prices, vesting schedules, and expiration dates, but does not disclose any new stock purchases or sales.
What are the exercise price ranges of the PolyPid (PYPD) CFO’s stock options?
The options have exercise prices from 2.6700 up to 123.0100 per Ordinary Share. Lower-priced grants are more recent, while the highest-priced grant of 20 underlying shares at 123.0100 dates back to an earlier option program.
When do the PolyPid (PYPD) CFO’s stock options expire?
The reported options expire on dates between 2027-03-08 and 2035-05-12. Earlier grants, such as those granted in 2017, expire in 2027, while later grants, including those tied to 2025 awards, expire in 2035.
What do the vesting footnotes in the PolyPid (PYPD) CFO Form 3 explain?
The footnotes describe grant dates and vesting schedules for each option award. Some option grants were already fully vested by dates like March 8, 2020, while others vest quarterly over multi‑year periods ending between 2026 and 2029.